Targeting WDR5/ATAD2 signaling by the CK2/Ikaros axis demonstrates therapeutic efficacy in T-ALL.

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a poor prognosis and limited options for targeted therapies. Identifying new molecular targets to develop novel therapeutic strategies is the pressing immediate issue in T-ALL. Here, we observed high expression of WD Repeat-Containing Protein 5 (WDR5) in T-ALL; with in vitro and in vivo models we demonstrated the oncogenic role of WDR5 in T-ALL by activating cell cycle signaling through its new downstream effector, ATPase family AAA domain-containing 2 (ATAD2).

Stem-like CD8 T cells in cancer.

Stem-like CD8 T cells (T) are a subset of immune cells with superior persistence and antitumor immunity. They are TCF1 PD-1 and important for the expansion of tumor specific CD8 T cells in response to checkpoint blockade immunotherapy. In acute infections, naïve CD8 T cells differentiate into effector and memory CD8 T cells; in cancer and chronic infections, persistent antigen stimulation can lead to T cell exhaustion.